Board of Directors

Niclas Lundqvist Chairman of the Board

Chairman of the Board since September 2020

Born: 1965

Education and experience:
Niclas Lundqvist has a bachelor's degree in law. and has previously worked at the Swedish Courts Administration and at a law firm with a main focus on contract law and corporate finance law. Entrepreneur who started a number of businesses, including a Swedish securities company with permission from the Swedish Financial Supervisory Authority. Extensive experience of board work in listed companies (including in Cantargia AB and Rhovac AB) and securities companies that are under the supervision of the Swedish Financial Supervisory Authority.

Shareholding:
Niclas Lundqvist does not own, privately or through companies, any shares in Coegin Pharma.

Tore Duvold Member of the Board and CEO

Board member and CEO since September 2020.

Born: 1968

Education and experience:
Tore Duvold has more than twenty years of experience from the pharmaceutical and biotechnology industry with thorough experience in dermatological diseases, antibiotics and kidney. Tore Duvold was President of Aker Biopharma AS 2014 - 2015 and Senior Vice President and part of the Group Management at LEO Pharma for a total of 15 years. Tore Duvold most recently came from Innovation Fund Denmark, where he took over as Deputy CEO in 2015 and was appointed CEO in April 2019. Tore Duvold has served on boards and advisory boards at both the Technical University of Denmark and the University of Copenhagen. Tore Duvold has a degree in organic chemistry from the universities of Bergen and Oslo and has a doctorate in bioorganic chemistry from the University of Louis Pasteur, France.

Shareholding:
Tore Duvold privately owns 1,000,000 warrants of the 2020/2024 series in Coegin Pharma.

Jesper Kihl Member of the board

Board member since September 2020.

Born: 1958

Education and experience:
Jesper Kihl has an MSc in Chemical Engineering from the Technical University of Denmark and has 40 years of experience from work in Life Science and Med Tech, mainly in senior positions. He spent 14 years as i.a. Vice President Global Regulatory Affairs and LEO Pharma A / S. Prior to that, he was 22 years old at Novo Nordisk in, among other things. manufacturing, quality, development, marketing and logistics. Jesper Kihl is and has been a member of several advisory boards, including for Biogenity and Gens & Associates, and works with funds, universities and other institutions.

Shareholding:
Jesper Kihl does not own, privately or through companies, any shares in Coegin Pharma.

Lars Persson Member of the board

Board member since September 2020.

Born: 1955

Education and experience:
Lars Persson has an MSc in chemistry and has over 25 years of experience from senior positions within MedTech and Venture Capital. Among other things, he has worked at Atos Medical AB, Stiftelsen Industrifonden and most recently as CEO of Almi Invest Syd AB. He also has experience as chairman of the board and board member in several companies, including Invent Medic Sweden AB.

Shareholding:
Lars Persson owns 385,000 shares privately, and 3,249,400 shares through Mandelträdet AB, which is 50 percent owned by Lars Persson, in Coegin Pharma.

Erlend Skagseth Member of the board

Board member since September 2020.

Born: 1955

Education and experience:
Erlend Skagseth has an MBA degree and 30 years of experience from R&D-based project management and business development as well as 15 years of experience in VC investments at an early stage. Erlend Skagseth is Managing Partner at Sarsia Seed and has participated in several turnarounds and negotiated several international contracts, licenses and exits. Has extensive experience from board work in development and growth companies.

Shareholding:
Sarisa Seed AS owns 14,483,802 shares in Coegin Pharma. Through Mitosis AS, Erlend Skagseth indirectly owns approximately 5 percent of the shares in Sarisa Seed AS.

Thoas Fioretos Member of the board

Boardmember since 2022.

Born: 1962

Education and experience:
Thoas Fioretos is a professor and chief physician at the Department of Clinical Genetics at Lund University. His research focuses on molecular and functional studies of genetic changes in leukemia and how such changes can be used for diagnostic and therapeutic purposes. Fioretos has authored more than 130 scientific articles. Thoas Fioretos is one of the founders of Cantargia AB and the bio-IT company Qlucore AB and is a board member of Cantargia AB and Qlucore AB and a deputy board member of Neodos AB.

Shareholding:
Thoas Fioretos does not own, privately or through companies, any shares in Coegin Pharma.